Cerebrolysin
A complex peptide preparation studied for neurotrophic effects, stroke recovery, traumatic brain injury, and cognitive function research.
Molecular Structure
Amino Acid Sequence
Molecular Formula
Molecular Weight
Half-Life
CAS Number
What is Cerebrolysin?
Cerebrolysin is a complex peptide preparation produced through standardized enzymatic breakdown of porcine brain tissue. Unlike most pharmacological compounds, it is not a single defined chemical entity but rather a standardized mixture containing low-molecular-weight peptides (approximately 25% of the preparation) and free amino acids (approximately 75%). The peptide components include fragments with biological activity resembling endogenous neurotrophic factors, particularly ciliary neurotrophic factor (CNTF)-like activity and to lesser extent brain-derived neurotrophic factor (BDNF)-like activity.
Cerebrolysin is notable in research as one of the most clinically studied neurotrophic preparations, with over five decades of clinical use primarily in Eastern Europe, Russia, China, and various other countries. The preparation is approved in over 50 countries for indications including vascular and Alzheimer’s-type dementia, stroke recovery, traumatic brain injury, and certain developmental disorders, though it is not FDA-approved in the United States or EMA-approved in the European Union. The compound has a substantial published clinical research base including randomized controlled trials and meta-analyses.
Mechanism of action
Cerebrolysin’s mechanisms of action have been investigated across multiple pathways:
- Neurotrophic factor-like effects: The peptide fraction includes components with biological activity resembling endogenous neurotrophic factors, particularly CNTF and to lesser extent NGF and BDNF, supporting neuronal survival, growth, and synaptic plasticity.
- Anti-apoptotic effects: Research has documented reduced neuronal apoptosis in models of cerebral ischemia, traumatic brain injury, and neurodegeneration through modulation of multiple cell death pathways.
- Reduced amyloid pathology: Studies in Alzheimer’s disease models have shown effects on amyloid plaque burden and tau pathology, consistent with potential disease-modifying effects in Alzheimer’s-type dementia.
- Synaptic plasticity: Effects on synaptic structure, function, and plasticity have been documented, providing mechanistic basis for cognitive improvements observed in clinical research.
- Anti-inflammatory effects: Reduction of neuroinflammatory markers including microglial activation and pro-inflammatory cytokine production has been observed in preclinical models.
These pathways are characterized in both preclinical models and human clinical research.
Research applications
Cerebrolysin has been investigated across several research domains, with the most active areas including:
- Acute ischemic stroke research: The largest body of Cerebrolysin clinical research is in acute ischemic stroke recovery. The CASTA trial and other large randomized studies have examined effects on neurological recovery, with meta-analyses finding modest benefits particularly in more severely affected populations when administered within 24-72 hours after stroke onset.
- Traumatic brain injury research: Studies in moderate and severe traumatic brain injury have examined effects on neurological recovery and functional outcomes, with effects generally modest but consistent across multiple trials.
- Vascular dementia and Alzheimer’s research: Clinical trials have examined Cerebrolysin in both vascular dementia and Alzheimer’s-type dementia, with some studies showing improvements in cognitive function and dementia severity scales, particularly in milder cases.
- Developmental disorders research: In some research contexts, Cerebrolysin has been examined for various pediatric developmental and learning disorders, though the evidence base for these uses is generally less developed than for adult indications.
- Cognitive enhancement research: Beyond approved indications, Cerebrolysin has been used in research examining cognitive enhancement, though evidence for benefits in healthy individuals without underlying neurological pathology is limited.
This compound is intended for laboratory research use only. It has not been approved for human therapeutic use by any regulatory agency.
Storage & reconstitution
Cerebrolysin is typically supplied as a sterile injectable solution rather than a lyophilized powder. Sealed vials should be stored at controlled room temperature protected from light. The product remains stable until the manufacturer’s labeled expiration date when stored properly.
After opening, refrigerate at 2-8°C and use within 28 days. Avoid repeated freeze-thaw cycles, which can degrade peptide components.
Visual inspection should be performed before each use. The solution should be clear and colorless to pale yellow. Reject any solution that appears cloudy, has unusual discoloration, or contains visible particulate matter.
For step-by-step reconstitution calculations, see our reconstitution calculator.
For laboratory research use only. The compound described on this page is intended exclusively for in vitro research and laboratory experimentation by qualified researchers and is not for human or veterinary use. It is not a drug, food, dietary supplement, or cosmetic, and has not been approved by the FDA, Health Canada, EMA, or any other regulatory authority for the diagnosis, treatment, cure, mitigation, or prevention of any disease or medical condition. The information provided on this page is for educational and reference purposes only and does not constitute medical advice. By accessing this content you confirm that you are a qualified researcher purchasing for legitimate laboratory purposes.